ABPI criticises “excessive” payment rates on branded medicines
The Association of the British Pharmaceutical Industry (ABPI) has warned that “rocketing payment rates are undermining the UK government’s efforts to make life sciences a key pillar of its industrial strategy”.
The government is proposing to raise the Statutory Scheme payment rate for newer branded medicines from 15.5% to 32.2% of subject companies’ NHS sales in the second half of 2025.
The ‘payment rate’ is the amount of revenue that companies are required to hand back to government on their sales of branded medicines to the NHS. It is an additional charge to the taxes paid by companies.
Currently, only a very small proportion (2%) of the total branded medicines market is subject to the Statutory Scheme, with the majority of companies opting into the Voluntary Scheme for Pricing, Access and Growth (VPAG), which tends to have enhanced terms and marginally lower rates.
The government’s proposal to raise the Statutory Scheme payment rate is intended to align the scheme with the 22.9% payment rate required for 2025 under the VPAG.
Richard Torbett, Chief Executive of the ABPI, said: “The government has rightly identified life sciences as a critical growth sector for the economy, but unless these excessive payment rates under both the VPAG, and Statutory Scheme are addressed, the UK will not see the growth and investment we all want.”
Comparing the UK to other countries
While no other country has an identical scheme to the UK, comparable sales rebate schemes in Germany have 7% payment rates, Ireland 9% payment rates, and France has an average 5.7% rate which is capped at 12%.
The UK invests a smaller share of overall healthcare costs on medicines than any comparable country. Just 9% of the UK’s overall healthcare spending is on medicines, compared to 17% in Germany and Italy and 15% in France1.
According to the King’s Fund, the UK tends to have much poorer health outcomes than its peers, coming 16th and 18th, respectively for preventable and treatable causes of mortality, those for which there tend to be medicines, in a basket of 19 comparable countries2.
Over the past decade, growth in the UK branded medicine market has been capped at between 1.1% (2014-2018) and 2% (2019-2023) per year. After accounting for inflation, this growth has declined by over a tenth (11%). In the same period, the NHS budget grew by a third in real terms (33%)3,4.
References
- The Kings Fund ‘How does the NHS compare to the health care systems of other countries?’ page 53
- The Kings Fund ‘How does the NHS compare to the health care systems of other countries?’ Figure 28, p81, 2022.
- NHS Funding and Expenditure, House of Commons Library, p.13
- ABPI analysis of 2014 PPRS and 2019 VPAS allowed growth rates (Base=2014) and outturn NHS Budget (RDEL) across the four nations adjusted for inflation (GDP inflator, October 2024)
Diana Spencer, Senior Digital Content Editor, DDW
